Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Short-term Investments (2016 - 2023)

BeOne Medicines (BEIGF) has disclosed Short-term Investments for 9 consecutive years, with $2.6 million as the latest value for Q4 2023.

  • Quarterly Short-term Investments fell 99.61% to $2.6 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Dec 2023, down 99.61% year-over-year, with the annual reading at $2.6 million for FY2023, 99.61% down from the prior year.
  • Short-term Investments for Q4 2023 was $2.6 million at BeOne Medicines, down from $107.0 million in the prior quarter.
  • The five-year high for Short-term Investments was $3.3 billion in Q4 2020, with the low at $2.6 million in Q4 2023.
  • Average Short-term Investments over 5 years is $1.4 billion, with a median of $1.0 billion recorded in 2022.
  • The sharpest move saw Short-term Investments skyrocketed 796.21% in 2020, then plummeted 99.61% in 2023.
  • Over 5 years, Short-term Investments stood at $364.7 million in 2019, then surged by 796.21% to $3.3 billion in 2020, then crashed by 31.41% to $2.2 billion in 2021, then tumbled by 70.33% to $665.3 million in 2022, then tumbled by 99.61% to $2.6 million in 2023.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $2.6 million, $107.0 million, and $105.7 million for Q4 2023, Q3 2023, and Q2 2023 respectively.